Catalyst

Slingshot members are tracking this event:

Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BXLT

100%

Additional Information

Additional Relevant Details Baxalta has dosed the first patient in its Phase 1, first-in-human clinical trial of BAX 826, a recombinant Factor VIII (rFVIII) treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life. BAX 826 is under investigation as Baxalta’s second extended half-life treatment based on ADVATE [Antihemophilic Factor (Recombinant)], the world's most prescribed FVIII treatment.

BAX 826 is a next-generation rFVIII treatment based on the full length ADVATE. The compound is modified using proprietary polysialic acid (PSA) technology licensed from Xenetic Biosciences, Inc. (OTCQB: XBIO) to extend its circulating half-life. Baxalta has partnered with Xenetic to develop novel forms of polysialylated blood coagulation factors, including FVIII. Xenetic’s PolyXen™ technology utilizes the biopolymer PSA in order to extend the circulating half-life and potentially improve the pharmacokinetic profile of therapeutic proteins, peptides, and small molecules. Preclinical studies indicated BAX 826 offered an extended circulating half-life compared to standard rFVIII.
http://investor.baxa...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bax 826, Half-life Factor Viii Treatment, Hemophilia A, Phase 1